Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
Immune checkpoint inhibitors (ICIs), Ipilimumab, Nivolumab, Pembrolizumab and Atezolizumab, have been applied in anti-tumor therapy and demonstrated exciting performance compared to conventional treatments. However, the unsatisfactory response rates, high recurrence and adaptive resistance limit the...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Frontiers Media S.A.
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/4593b770644d4d20a393ea8ad3438eb1 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|